- Home
- PRPO vs NLSP Comparison
PRPO vs NLSP Comparison
Compare PRPO & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- NLSP
- Stock Information
- Founded
- PRPO N/A
- NLSP 2015
- Country
- PRPO United States
- NLSP Switzerland
- Employees
- PRPO 57
- NLSP N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- NLSP Health Care
- Exchange
- PRPO Nasdaq
- NLSP Nasdaq
- Market Cap
- PRPO 9.5M
- NLSP 243.8M
- IPO Year
- PRPO N/A
- NLSP 2021
- Fundamental
- Price
- PRPO $6.59
- NLSP $4.96
- Analyst Decision
- PRPO
- NLSP
- Analyst Count
- PRPO 0
- NLSP 0
- Target Price
- PRPO N/A
- NLSP N/A
- AVG Volume (30 Days)
- PRPO 7.9K
- NLSP 34.6K
- Earning Date
- PRPO 11-11-2024
- NLSP 11-01-2024
- Dividend Yield
- PRPO N/A
- NLSP N/A
- EPS Growth
- PRPO N/A
- NLSP N/A
- EPS
- PRPO N/A
- NLSP N/A
- Revenue
- PRPO $16,719,999.00
- NLSP N/A
- Revenue This Year
- PRPO $75.18
- NLSP N/A
- Revenue Next Year
- PRPO N/A
- NLSP N/A
- P/E Ratio
- PRPO N/A
- NLSP N/A
- Revenue Growth
- PRPO 52.61
- NLSP N/A
- 52 Week Low
- PRPO $4.31
- NLSP $4.08
- 52 Week High
- PRPO $8.99
- NLSP $29.68
- Technical
- Relative Strength Index (RSI)
- PRPO 52.82
- NLSP 46.37
- Support Level
- PRPO $6.42
- NLSP $4.52
- Resistance Level
- PRPO $6.99
- NLSP $5.64
- Average True Range (ATR)
- PRPO 0.33
- NLSP 0.48
- MACD
- PRPO -0.04
- NLSP 0.07
- Stochastic Oscillator
- PRPO 69.91
- NLSP 55.44
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.